Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Cabometyx | cabozantinib | Advanced or metastatic renal cell carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Rezurock | belumosudil | Graft-versus-host disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Opdualag | nivolumab and relatlimab | unresectable or metastatic melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Rinvoq | upadacitinib | ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete | ||
Imfinzi and Imjudo | durvalumab and tremelimumab | unresectable hepatocellular carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Sohonos | palovarotene | Fibrodysplasia Ossificans Progressiva | Reimburse with clinical criteria and/or conditions | Complete | ||
Tavneos | avacopan | Antineutrophil cytoplasmic antibody-associated vasculitis | Do not reimburse | Complete | ||
Vyalev | foslevodopa foscarbidopa | Parkinson's disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Koselugo | selumetinib | Neurofibromatosis type 1 | Reimburse with clinical criteria and/or conditions | Complete | ||
Carvykti | ciltacabtagene autoleucel | Relapsed or refractory multiple myeloma | Reimburse with clinical criteria and/or conditions | Complete |